9th Aug 2012 11:24
For Immediate Release | 09 August 2012 |
Alliance Pharma plc
TR-1: Notification of Major Interest in Shares
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Alliance Pharma plc | |||||||||||||||||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||||||||||||||||
An acquisition or disposal of voting rights | ||||||||||||||||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||||||||||||||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||||||||||||||||
An event changing the breakdown of voting rights | ||||||||||||||||||
Other (please specify): | On market transfers between indirect and direct funds | √ | ||||||||||||||||
3. Full name of person(s) subject to thenotification obligation: | Aviva plc & its subsidiaries | |||||||||||||||||
4. Full name of shareholder(s) (if different from 3.): |
| |||||||||||||||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 07 August 2012 | |||||||||||||||||
6. Date on which issuer notified: | 08 August 2012 | |||||||||||||||||
7. Threshold(s) that is/are crossed orreached: | 10% to 9% Change at Direct Interest Level | |||||||||||||||||
8. Notified details: | |||||||||||
A: Voting rights attached to shares | |||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | |||||||
Direct | Direct | Indirect | Direct | Indirect | |||||||
Ordinary SharesGB0031030819 | 24,316,755 | 24,316,755 | 24,316,755 | 23,863,562 | 453,193 | 9.94% | 0.19% | ||||
| |||||||||||
B: Qualifying Financial Instruments | |||||||||||
Resulting situation after the triggering transaction | |||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |
| Nominal | Delta | ||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
24,316,755 | 10.13% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: ·; Aviva plc (Parent Company) ·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: |
Figures are based on a revised total number of voting rights of 240,067,284.
| |
14. Contact name: | Michael Dunhill, Aviva plc | |
15. Contact telephone number: | 01603 685988 | |
Related Shares:
Alliance Pharma